Leveraging Autologous Tumor-Initiating Cells & Dendritic Cells as a Platform for Personal Cancer Vaccines

• Short-term autologous cancer cell cultures enriched for tumour-initiating cells may be a better source of patient-specific antigens than whole tumour or neo-antigen prediction models
• Antigen presentation by autologous dendritic cells provides some advantages over other means of antigen presentation
• Feasibility, safety, and suggestion of efficacy of such patient-specific vaccines have documented in several cancers

Speakers:

Robert Dillman

Chief Medical Officer

AiVita Biomedical